Literature DB >> 25037611

The value of 4-month neurocognitive function as an endpoint in brain metastases trials.

Shunsuke Onodera1, Hidefumi Aoyama, Khin Khin Tha, Naoki Hashimoto, Atsuhito Toyomaki, Satoshi Terae, Hiroki Shirato.   

Abstract

To investigate whether the neurocognitive function at 4 months could be a relevant primary endpoint in clinical trials dealing with brain metastases, we created a Japanese neurocognitive battery and examined the changes in patients' neurocognitive function for 1 year after their brain radiotherapy. In this prospective pilot study, we enrolled 27 patients (20 patients who received whole-brain radiation therapy [WBRT] and seven who received stereotactic irradiation [STI] alone) between March 2009 and December 2010. The follow-up neurocognitive data at 4, 8 and 12 months were available in 22 (17 WBRT, 5 STI), 19 patients (14 WBRT, 5 STI) and 13 patients (9 WBRT, 4 STI), respectively. Among the patients who received WBRT, significant deterioration in delayed memory compared to the baseline (p = 0.04) was observed at 4 months, and at 8 months, significant improvements were observed in immediate memory compared to the baseline (p = 0.008) and 4-months scores (p = 0.005). At 12 months, however, the immediate memory scores had returned to the baseline. Similar trends were observed in other functions (delayed memory, attention and executive functions). In these patients, the correlations between 4-months scores of neurocognitive functions and 12-months scores were significant in immediate memory (γ = 0.68, p = 0.004), delayed memory (γ = 0.738, p = 0.023) and attention (γ = 0.817, p = 0.007). Among the patients who received STI, no significant changes were observed in any functions. These results suggest that 4-months changes in neurocognitive functions were transient but could also be a premonitory index for predicting the neurocognitive function 1 year or later after brain radiation therapy.

Entities:  

Mesh:

Year:  2014        PMID: 25037611     DOI: 10.1007/s11060-014-1550-y

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  25 in total

1.  Age and educational influences on RBANS index scores in a nondemented geriatric sample.

Authors:  Samuel T Gontkovsky; James W Mold; William W Beatty
Journal:  Clin Neuropsychol       Date:  2002-08       Impact factor: 3.535

Review 2.  Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group.

Authors:  Nancy U Lin; Jeffrey S Wefel; Eudocia Q Lee; David Schiff; Martin J van den Bent; Riccardo Soffietti; John H Suh; Michael A Vogelbaum; Minesh P Mehta; Janet Dancey; Mark E Linskey; D Ross Camidge; Hidefumi Aoyama; Paul D Brown; Susan M Chang; Steven N Kalkanis; Igor J Barani; Brigitta G Baumert; Laurie E Gaspar; F Stephen Hodi; David R Macdonald; Patrick Y Wen
Journal:  Lancet Oncol       Date:  2013-09       Impact factor: 41.316

3.  Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial.

Authors:  Hidefumi Aoyama; Hiroki Shirato; Masao Tago; Keiichi Nakagawa; Tatsuya Toyoda; Kazuo Hatano; Masahiro Kenjyo; Natsuo Oya; Saeko Hirota; Hiroki Shioura; Etsuo Kunieda; Taisuke Inomata; Kazushige Hayakawa; Norio Katoh; Gen Kobashi
Journal:  JAMA       Date:  2006-06-07       Impact factor: 56.272

4.  Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone.

Authors:  Hidefumi Aoyama; Masao Tago; Norio Kato; Tatsuya Toyoda; Masahiro Kenjyo; Saeko Hirota; Hiroki Shioura; Taisuke Inomata; Etsuo Kunieda; Kazushige Hayakawa; Keiichi Nakagawa; Gen Kobashi; Hiroki Shirato
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-08-01       Impact factor: 7.038

5.  Memory function before and after whole brain radiotherapy in patients with and without brain metastases.

Authors:  Grit Welzel; Katharina Fleckenstein; Jörg Schaefer; Brigitte Hermann; Uta Kraus-Tiefenbacher; Sabine K Mai; Frederik Wenz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-04-28       Impact factor: 7.038

6.  Repeatable battery for the assessment of neuropsychological status as a screening test in schizophrenia I: sensitivity, reliability, and validity.

Authors:  J M Gold; C Queern; V N Iannone; R W Buchanan
Journal:  Am J Psychiatry       Date:  1999-12       Impact factor: 18.112

7.  The validity of the repeatable battery of neuropsychological status in acute stroke.

Authors:  M C Wilde
Journal:  Clin Neuropsychol       Date:  2006-12       Impact factor: 3.535

8.  Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial.

Authors:  Christina A Meyers; Jennifer A Smith; Andrea Bezjak; Minesh P Mehta; James Liebmann; Tim Illidge; Ian Kunkler; Jean-Michel Caudrelier; Peter D Eisenberg; Jacobus Meerwaldt; Ross Siemers; Christian Carrie; Laurie E Gaspar; Walter Curran; See-Chun Phan; Richard A Miller; Markus F Renschler
Journal:  J Clin Oncol       Date:  2004-01-01       Impact factor: 44.544

9.  Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases.

Authors:  Minesh P Mehta; Patrick Rodrigus; C H J Terhaard; Aroor Rao; John Suh; Wilson Roa; Luis Souhami; Andrea Bezjak; Mark Leibenhaut; Ritsuko Komaki; Christopher Schultz; Robert Timmerman; Walter Curran; Jennifer Smith; See-Chun Phan; Richard A Miller; Markus F Renschler
Journal:  J Clin Oncol       Date:  2003-07-01       Impact factor: 44.544

10.  Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial.

Authors:  Eric L Chang; Jeffrey S Wefel; Kenneth R Hess; Pamela K Allen; Frederick F Lang; David G Kornguth; Rebecca B Arbuckle; J Michael Swint; Almon S Shiu; Moshe H Maor; Christina A Meyers
Journal:  Lancet Oncol       Date:  2009-10-02       Impact factor: 41.316

View more
  8 in total

Review 1.  Management of melanoma brain metastases.

Authors:  Mary Frances McAleer; Dae W Kim; Van A Trinh; Wen-Jen Hwu
Journal:  Melanoma Manag       Date:  2015-08-10

2.  The Impact of Stereotactic or Whole Brain Radiotherapy on Neurocognitive Functioning in Adult Patients with Brain Metastases: A Systematic Review and Meta-Analysis.

Authors:  Eva Elisabeth van Grinsven; Steven H J Nagtegaal; Joost J C Verhoeff; Martine J E van Zandvoort
Journal:  Oncol Res Treat       Date:  2021-09-03       Impact factor: 2.825

3.  Neurocognitive functioning and health-related quality of life in patients treated with stereotactic radiotherapy for brain metastases: a prospective study.

Authors:  Esther J J Habets; Linda Dirven; Ruud G Wiggenraad; Antoinette Verbeek-de Kanter; Geert J Lycklama À Nijeholt; Hanneke Zwinkels; Martin Klein; Martin J B Taphoorn
Journal:  Neuro Oncol       Date:  2015-09-18       Impact factor: 12.300

4.  Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial.

Authors:  Paul D Brown; Kurt Jaeckle; Karla V Ballman; Elana Farace; Jane H Cerhan; S Keith Anderson; Xiomara W Carrero; Fred G Barker; Richard Deming; Stuart H Burri; Cynthia Ménard; Caroline Chung; Volker W Stieber; Bruce E Pollock; Evanthia Galanis; Jan C Buckner; Anthony L Asher
Journal:  JAMA       Date:  2016-07-26       Impact factor: 56.272

5.  Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary utility in adult neuro-oncology.

Authors:  Ashlee R Loughan; Sarah E Braun; Autumn Lanoye
Journal:  Neurooncol Pract       Date:  2018-12-08

Review 6.  Low-Intensity MR-Guided Focused Ultrasound Mediated Disruption of the Blood-Brain Barrier for Intracranial Metastatic Diseases.

Authors:  Ying Meng; Suganth Suppiah; Shanan Surendrakumar; Luca Bigioni; Nir Lipsman
Journal:  Front Oncol       Date:  2018-08-28       Impact factor: 6.244

7.  Cognitive functioning and predictors thereof in patients with 1-10 brain metastases selected for stereotactic radiosurgery.

Authors:  Wietske C M Schimmel; Karin Gehring; Patrick E J Hanssens; Margriet M Sitskoorn
Journal:  J Neurooncol       Date:  2019-09-24       Impact factor: 4.130

Review 8.  Cognitive effects of stereotactic radiosurgery in adult patients with brain metastases: A systematic review.

Authors:  Wietske C M Schimmel; Karin Gehring; Daniëlle B P Eekers; Patrick E J Hanssens; Margriet M Sitskoorn
Journal:  Adv Radiat Oncol       Date:  2018-07-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.